Canadians may be eligible for a piece of this class-action involving a drug used to treat depression, schizophrenia
Canadians have until August 27 to claim a share of a $4.75 million settlement regarding the drug Rexulti.Summary
A deadline of August 27 is approaching for Canadians to file claims in a $4.75 million class-action settlement involving the antipsychotic medication Rexulti. The settlement, approved by the Quebec Superior Court in November, addresses claims against Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc. regarding the drug's use in treating schizophrenia and depression.
The class action is specifically for individuals prescribed Rexulti since February 2017 who subsequently developed impulse-control disorders, such as compulsive gambling, shopping, or binge-eating. While the settlement involves no admission of liability by the pharmaceutical companies, it serves as a compromise for affected patients and their families.
Compensation amounts vary significantly based on the severity of the condition, with payouts ranging from approximately $6,500 for mild cases to over $102,000 for more severe instances.
(Source：Bnn Bloomberg)